I
InflaRx
Developing new therapeutics in the terminal complement space
About InflaRx
InflaRx N.V., headquartered in Jena, Germany, is a clinical-stage biopharmaceutical company specializing in the development of monoclonal antibodies that target activation products of the complement system. The company focuses on addressing acute and chronic inflammation through innovative therapeutic solutions. InflaRx's primary clients include healthcare providers and research institutions that require advanced treatments for life-threatening inflammatory diseases. Operating in the biopharmaceutical market, InflaRx employs a business model centered on research and development, clinical trials, and eventual commercialization of its drug candidates. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. InflaRx's lead drug candidate, IFX-1, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical phase II development. Another promising candidate, IFX-2, is in preclinical development and aims to offer highly potent anti-complement C5a antibody solutions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2007
- Headquarters
- Planegg, Germany
- Listing
- IPO 2018
- Employees
- 46
- Open positions
- None listed
- Dealroom signal
- 31.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Cardiology and cardiovascular, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | May 2026 | $150M | — | ADAR1 Capital Management · Great Point Partners · Columbia Threadneedle Investments · Coastlands Capital | ↗ |
| POST IPO EQUITY✓Other financing | Feb 2025 | $30M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for InflaRx is 3.9K monthly website visits, up 129.4% over the last three months. InflaRx's team declined 24.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Affentranger Associates
Series A1 investor entered at this stage
bm-t Beteiligungsmanagement Thüringen
Series B and later12 investors entered at this stage
Bain Capital Life Sciences
Bain Capital
Cormorant Asset Management
RA Capital Management
ADAR1 Capital Management
Great Point Partners
Columbia Threadneedle Investments- CCCoastlands Capital
Squadron Capital Management
Farallon Capital Management
TCGX
Sirenia Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about InflaRx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InflaRx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.